Extraction, Cloning and Expression of RTB, as a Vaccine Adjuvant/Carrier, in E. coli and Production of Mouse Polyclonal Antibody (Anti-B chain Abs) Extraction, cloning and coxpression of RTB in E. coli and poly clonal antibody production.
Iranian Journal of Pharmaceutical Sciences,
Vol. 7 No. 4 (2011),
1 October 2011
,
Page 247-254
https://doi.org/10.22037/ijps.v7.41307
Abstract
Ricin, the toxic lectin extracted from the castor bean plant (Ricinus communis), consists of an A chain (RTA) and a B chain (RTB). Anti-A chain Abs and anti-B chain Abs can neutralize toxins in vivo and in vitro via blocking the binding of the toxin to the cell. Also, RTB protein is able to serve as an antigen deliver to the mucosal immune system and act as an immunoadjuant. Here, the genomic DNA was extracted from the fresh leave of the castor plant. The RTB gene was amplified by PCR. The prokaryotic expression vector pET-28a (+)- RTB was constructed, and used to transform E. coli Rosetta(DE3). The expression of recombinant protein induced by IPTG was examined by SDS-PAGE. Western blot were used to determine immunoreactivity of RTB-His by a rabbit monoclonal antibodies against His-tag. The SDS-PAGE profile exhibited the constructed prokaryotic expression efficiently produced RTB at the 1 mmol/L of IPTG. Addition of glycine and Triton X-100 enhanced native extracellular protein excreted into the culture medium. Anti-RTB polyclonal serum was generated by repeated immunization of mice with recombinant RTB protein. Finally, the antigenicity of recombinant RTB was identified by Western blot and indirect ELISA. A relative high titer of anti-RTB antibody was detected after the fourth injection. Western blot analysis was carried out with the polyclonal antibody revealed almost a 32-kDa band which corresponds to RTB protein. In conclusion, we herein report the expression of fully biologically active RTB as a plant lectin by a new strategy. This recombinant Ricin protein could be a promising drug for cancer therapy, vaccine as an immune response enhancement and even viral infected cells.
- Cloning
- E. coli Rosetta (DE3)
- xpression
- Lectin
- Polyclonal antibody
- Ricin toxin B.
How to Cite
References
[2] Lord JM, Roberts LM, Robertus JD. Ricin: structure, mode of action, and some current applications. FASEB 1988; 13:196-204.
[3] Sphyris N, Lord JM, Wales R, Roberts LM. Mutational analysis of the ricinus lectin B-chains. J Biol Chem 1995; 270: 20292-7.
[4] Medina-Bolivar F, Wright R, Funk V, Sentz D, Barroso L, Wilkins TD, Petri W Jr, Cramer CL. A non-toxic lectin for antigen delivery of plantbased mucosal vaccines. Vaccine 2003; 21: 997-1005.
[5] Richardson PT, Hussain K, Woodland HR, Lord JM, Roberts LM. The effects of N-glycosylation on the lectin activity of recombinant ricin B chain. Carbohydrate Res 1991; 213: 19-25.
[6] Wales R, Richardson PT, Roberts LM, Lord JM. Recombinant ricin B chain fragments containing a single galactose binding site retain lectin activity.Arch Biochem Biophys 1992; 294: 291-6.
[7] Maddaloni M, Cooke C, Wilkinson R, Stout AV, Eng L, Pincus SH. Immunological characteristicsa ssociated with the protective efficacy of antibodies to Ricin. J Immunol 2004; 172: 62218.
[8] Olson MA, Carra JH, Roxas-Duncan V, Wannemacher RW, Smith LA, Millard CB. Finding a new vaccine in the ricin protein fold. Protein Eng Des Sel 2004; 17: 391-7.
[9] Nak-Won Choi, Mary K. Estes, William H.R. Langridge. Mucosal immunization with a ricin toxin B subunit–rotavirus NSP4 fusion protein stimulates a Th1 lymphocyte response. J Biotechnol 2006; 121: 272-83.
[10] Hussain K, Bowler C, Roberts LM, Lord JM.Expression of ricin B chain in Escherichia coli. FEBS Lett 1989; 244: 383-7.
[11] Choi JH, Lee SY. Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl Microbiol Biotechnol 2004; 64: 625-35.
[12] Novy R, Drott D, Yaeger K, Mierendorf R.Overcoming the codon bias of E. coli for enhanced protein expression. Innovations 2001; 12: 1-4.
[13] Robertus JD, Ready MP. Ricin B chain and discoidin I share a common primitive protein fold. J Biol Chem 1984; 259: 13953-95.
[14] Georgiou G, Segatori L. Preparative expression of secreted proteins in bacteria: status report future prospects. Curr Opin Biotechnol 2005; 16: 538-45.
[15] Hoffmann F, van den Heuvel JJ, Zidek N, Rinas U. Minimizing inclusion body formation during recombinant protein production in Escherichia coli at bench and pilot plant scale. Enzyme Microbial Technol 2004; 34: 235-41.
[16] Hunke S, Betton JM. Temperature effect on inclusion body formation and stress response in the periplasm of Escherichia coli. Mol Microbiol 2003; 50: 1579-89.
[17] Kadokura H, Katzen F, Beckwith J. Protein disulfide bond formation in prokaryotes. Annu Rev Biochem 2003; 72: 111-35.
[18] Lee SY, Choi JH, Lee SJ. Secretory production of therapeutic proteins in Escherichia coli. Methods Mol Biol 2005; 308: 31-42.
[19] Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed. New York: Cold Spring Harbor Laboratory Press; 1989.
- Abstract Viewed: 340 times
- IJPS_Volume 7_Issue 4_Pages 247-254 Downloaded: 237 times